Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial

To examine the long-term survival outcome of dabrafenib in combination with trametinib in Chinese patients with unresectable or metastatic acral/cutaneous melanoma with BRAF-V600 mutation and to explore potential predictors of effectiveness. This was a long-term follow-up of Chinese patients with un...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology 2021-08, Vol.11, p.720044-720044
Main Authors: Mao, Lili, Ding, Ya, Bai, Xue, Sheng, Xinan, Dai, Jie, Chi, Zhihong, Cui, Chuanliang, Kong, Yan, Fan, Yun, Xu, Yanjun, Wang, Xuan, Tang, Bixia, Lian, Bin, Yan, Xieqiao, Li, Siming, Zhou, Li, Wei, Xiaoting, Li, Caili, Guo, Jun, Zhang, Xiaoshi, Si, Lu
Format: Article
Language:English
Subjects:
acral melanoma
BRAF
dabrafenib
melanoma
Oncology
trametinib
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c462t-7bba19d880485158ced74993777017813733a85b38a9f5ab26c6b83cabb5152b3
cites cdi_FETCH-LOGICAL-c462t-7bba19d880485158ced74993777017813733a85b38a9f5ab26c6b83cabb5152b3
container_end_page 720044
container_issue
container_start_page 720044
container_title Frontiers in oncology
container_volume 11
creator Mao, Lili
Ding, Ya
Bai, Xue
Sheng, Xinan
Dai, Jie
Chi, Zhihong
Cui, Chuanliang
Kong, Yan
Fan, Yun
Xu, Yanjun
Wang, Xuan
Tang, Bixia
Lian, Bin
Yan, Xieqiao
Li, Siming
Zhou, Li
Wei, Xiaoting
Li, Caili
Guo, Jun
Zhang, Xiaoshi
Si, Lu
description To examine the long-term survival outcome of dabrafenib in combination with trametinib in Chinese patients with unresectable or metastatic acral/cutaneous melanoma with BRAF-V600 mutation and to explore potential predictors of effectiveness. This was a long-term follow-up of Chinese patients with unresectable or metastatic BRAF V600-mutant acral/cutaneous melanoma administered dabrafenib (150 mg twice daily) plus trametinib (2 mg once daily) in an open-label, multicenter, single-arm, phase IIa study (NCT02083354). Efficacy endpoints included objective response rate (ORR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). The impacts of baseline characteristics on PFS and OS were analyzed. A total of sixty patients were included. The median age was 48 years, and 24 patients (40.0%) were male. Totally 12 individuals (20.0%) had acral melanoma, and 45 (75.0%) had failed previous systemic therapy. Up to July 2020, the median duration of follow-up was 37.0 (95% confidence interval [CI] 29.1-44.9) months. The updated ORR was 71.7% (95%CI 60.3%-83.1%). The 3-year OS rate was 28.8% (95%CI 19.1-43.6%) in the overall population, and 35.7% (95%CI 15.5-82.4%) in acral melanoma patients. The median DOR was 7.5 months (95%CI 4.5 to 10.5). Baseline normal lactic dehydrogenase (LDH), metastatic organ sites
doi_str_mv 10.3389/fonc.2021.720044
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_3c16dfb2acaa443b86ee7bdc3445159e</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_3c16dfb2acaa443b86ee7bdc3445159e</doaj_id><sourcerecordid>2571924518</sourcerecordid><originalsourceid>FETCH-LOGICAL-c462t-7bba19d880485158ced74993777017813733a85b38a9f5ab26c6b83cabb5152b3</originalsourceid><addsrcrecordid>eNpVkk1vEzEQhlcIRKvSOyfkIwc29dreLw5IaSAQKVEjmgA3a-ydTbbyroO9G8S_5CfhJaVqffHXO8_M2G8UvU7ohPOivKptpyeMsmSSM0qFeBadM8ZFXAr-4_mj9Vl06f0dDSNLaUL5y-iMi5SKvMzOoz83R3RgDLkd3LE5giG2JmvoG-x6T743_Z5sO4cedQ_KILGOrLAH3weJJtdfp3PyLaM0Xg09dD2Z6gC7mo0btIMPWgOdbYFMq7bpGt-jw4p8BOWgxq5RZG2CauOgxT7cq_dkabtdvEHXkrk1xv6Kt4exJCCrwYSUoSx078ht0-0MxtMgW-_BI1ksIGAaMK-iFzUYj5f380W0nX_azL7Ey5vPi9l0GWuRsT7OlYKkrIqCiiJN0kJjlYuy5Hme0yQvEp5zDkWqeAFlnYJimc5UwTUoFeRM8YtoceJWFu7kwTUtuN_SQiP_HVi3k-BCwQYl10lW1YqBBhCCqyJDzFWluRCBVWJgfTixDoNqsRqbDM_4BPr0pmv2cmePshCMhQ4C4O09wNmfA_peto3XaMzpGyRL86RkIVsRpPQk1c5677B-SJNQOfpKjr6So6_kyVch5M3j8h4C_ruI_wUpQMxY</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2571924518</pqid></control><display><type>article</type><title>Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial</title><source>PubMed Central Free</source><creator>Mao, Lili ; Ding, Ya ; Bai, Xue ; Sheng, Xinan ; Dai, Jie ; Chi, Zhihong ; Cui, Chuanliang ; Kong, Yan ; Fan, Yun ; Xu, Yanjun ; Wang, Xuan ; Tang, Bixia ; Lian, Bin ; Yan, Xieqiao ; Li, Siming ; Zhou, Li ; Wei, Xiaoting ; Li, Caili ; Guo, Jun ; Zhang, Xiaoshi ; Si, Lu</creator><creatorcontrib>Mao, Lili ; Ding, Ya ; Bai, Xue ; Sheng, Xinan ; Dai, Jie ; Chi, Zhihong ; Cui, Chuanliang ; Kong, Yan ; Fan, Yun ; Xu, Yanjun ; Wang, Xuan ; Tang, Bixia ; Lian, Bin ; Yan, Xieqiao ; Li, Siming ; Zhou, Li ; Wei, Xiaoting ; Li, Caili ; Guo, Jun ; Zhang, Xiaoshi ; Si, Lu</creatorcontrib><description>To examine the long-term survival outcome of dabrafenib in combination with trametinib in Chinese patients with unresectable or metastatic acral/cutaneous melanoma with BRAF-V600 mutation and to explore potential predictors of effectiveness. This was a long-term follow-up of Chinese patients with unresectable or metastatic BRAF V600-mutant acral/cutaneous melanoma administered dabrafenib (150 mg twice daily) plus trametinib (2 mg once daily) in an open-label, multicenter, single-arm, phase IIa study (NCT02083354). Efficacy endpoints included objective response rate (ORR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). The impacts of baseline characteristics on PFS and OS were analyzed. A total of sixty patients were included. The median age was 48 years, and 24 patients (40.0%) were male. Totally 12 individuals (20.0%) had acral melanoma, and 45 (75.0%) had failed previous systemic therapy. Up to July 2020, the median duration of follow-up was 37.0 (95% confidence interval [CI] 29.1-44.9) months. The updated ORR was 71.7% (95%CI 60.3%-83.1%). The 3-year OS rate was 28.8% (95%CI 19.1-43.6%) in the overall population, and 35.7% (95%CI 15.5-82.4%) in acral melanoma patients. The median DOR was 7.5 months (95%CI 4.5 to 10.5). Baseline normal lactic dehydrogenase (LDH), metastatic organ sites&lt;3 and complete response to combination therapy with dabrafenib plus trametinib were associated with improved PFS and OS. Dabrafenib combined with trametinib confer long-term survival in Chinese patients with BRAF V600-mutant, unresectable or metastatic acral/cutaneous melanoma. https://clinicaltrials.gov/ct2/show/NCT02083354, identifier NCT02083354.</description><identifier>ISSN: 2234-943X</identifier><identifier>EISSN: 2234-943X</identifier><identifier>DOI: 10.3389/fonc.2021.720044</identifier><identifier>PMID: 34504796</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>acral melanoma ; BRAF ; dabrafenib ; melanoma ; Oncology ; trametinib</subject><ispartof>Frontiers in oncology, 2021-08, Vol.11, p.720044-720044</ispartof><rights>Copyright © 2021 Mao, Ding, Bai, Sheng, Dai, Chi, Cui, Kong, Fan, Xu, Wang, Tang, Lian, Yan, Li, Zhou, Wei, Li, Guo, Zhang and Si.</rights><rights>Copyright © 2021 Mao, Ding, Bai, Sheng, Dai, Chi, Cui, Kong, Fan, Xu, Wang, Tang, Lian, Yan, Li, Zhou, Wei, Li, Guo, Zhang and Si 2021 Mao, Ding, Bai, Sheng, Dai, Chi, Cui, Kong, Fan, Xu, Wang, Tang, Lian, Yan, Li, Zhou, Wei, Li, Guo, Zhang and Si</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c462t-7bba19d880485158ced74993777017813733a85b38a9f5ab26c6b83cabb5152b3</citedby><cites>FETCH-LOGICAL-c462t-7bba19d880485158ced74993777017813733a85b38a9f5ab26c6b83cabb5152b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422804/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422804/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34504796$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mao, Lili</creatorcontrib><creatorcontrib>Ding, Ya</creatorcontrib><creatorcontrib>Bai, Xue</creatorcontrib><creatorcontrib>Sheng, Xinan</creatorcontrib><creatorcontrib>Dai, Jie</creatorcontrib><creatorcontrib>Chi, Zhihong</creatorcontrib><creatorcontrib>Cui, Chuanliang</creatorcontrib><creatorcontrib>Kong, Yan</creatorcontrib><creatorcontrib>Fan, Yun</creatorcontrib><creatorcontrib>Xu, Yanjun</creatorcontrib><creatorcontrib>Wang, Xuan</creatorcontrib><creatorcontrib>Tang, Bixia</creatorcontrib><creatorcontrib>Lian, Bin</creatorcontrib><creatorcontrib>Yan, Xieqiao</creatorcontrib><creatorcontrib>Li, Siming</creatorcontrib><creatorcontrib>Zhou, Li</creatorcontrib><creatorcontrib>Wei, Xiaoting</creatorcontrib><creatorcontrib>Li, Caili</creatorcontrib><creatorcontrib>Guo, Jun</creatorcontrib><creatorcontrib>Zhang, Xiaoshi</creatorcontrib><creatorcontrib>Si, Lu</creatorcontrib><title>Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial</title><title>Frontiers in oncology</title><addtitle>Front Oncol</addtitle><description>To examine the long-term survival outcome of dabrafenib in combination with trametinib in Chinese patients with unresectable or metastatic acral/cutaneous melanoma with BRAF-V600 mutation and to explore potential predictors of effectiveness. This was a long-term follow-up of Chinese patients with unresectable or metastatic BRAF V600-mutant acral/cutaneous melanoma administered dabrafenib (150 mg twice daily) plus trametinib (2 mg once daily) in an open-label, multicenter, single-arm, phase IIa study (NCT02083354). Efficacy endpoints included objective response rate (ORR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). The impacts of baseline characteristics on PFS and OS were analyzed. A total of sixty patients were included. The median age was 48 years, and 24 patients (40.0%) were male. Totally 12 individuals (20.0%) had acral melanoma, and 45 (75.0%) had failed previous systemic therapy. Up to July 2020, the median duration of follow-up was 37.0 (95% confidence interval [CI] 29.1-44.9) months. The updated ORR was 71.7% (95%CI 60.3%-83.1%). The 3-year OS rate was 28.8% (95%CI 19.1-43.6%) in the overall population, and 35.7% (95%CI 15.5-82.4%) in acral melanoma patients. The median DOR was 7.5 months (95%CI 4.5 to 10.5). Baseline normal lactic dehydrogenase (LDH), metastatic organ sites&lt;3 and complete response to combination therapy with dabrafenib plus trametinib were associated with improved PFS and OS. Dabrafenib combined with trametinib confer long-term survival in Chinese patients with BRAF V600-mutant, unresectable or metastatic acral/cutaneous melanoma. https://clinicaltrials.gov/ct2/show/NCT02083354, identifier NCT02083354.</description><subject>acral melanoma</subject><subject>BRAF</subject><subject>dabrafenib</subject><subject>melanoma</subject><subject>Oncology</subject><subject>trametinib</subject><issn>2234-943X</issn><issn>2234-943X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkk1vEzEQhlcIRKvSOyfkIwc29dreLw5IaSAQKVEjmgA3a-ydTbbyroO9G8S_5CfhJaVqffHXO8_M2G8UvU7ohPOivKptpyeMsmSSM0qFeBadM8ZFXAr-4_mj9Vl06f0dDSNLaUL5y-iMi5SKvMzOoz83R3RgDLkd3LE5giG2JmvoG-x6T743_Z5sO4cedQ_KILGOrLAH3weJJtdfp3PyLaM0Xg09dD2Z6gC7mo0btIMPWgOdbYFMq7bpGt-jw4p8BOWgxq5RZG2CauOgxT7cq_dkabtdvEHXkrk1xv6Kt4exJCCrwYSUoSx078ht0-0MxtMgW-_BI1ksIGAaMK-iFzUYj5f380W0nX_azL7Ey5vPi9l0GWuRsT7OlYKkrIqCiiJN0kJjlYuy5Hme0yQvEp5zDkWqeAFlnYJimc5UwTUoFeRM8YtoceJWFu7kwTUtuN_SQiP_HVi3k-BCwQYl10lW1YqBBhCCqyJDzFWluRCBVWJgfTixDoNqsRqbDM_4BPr0pmv2cmePshCMhQ4C4O09wNmfA_peto3XaMzpGyRL86RkIVsRpPQk1c5677B-SJNQOfpKjr6So6_kyVch5M3j8h4C_ruI_wUpQMxY</recordid><startdate>20210824</startdate><enddate>20210824</enddate><creator>Mao, Lili</creator><creator>Ding, Ya</creator><creator>Bai, Xue</creator><creator>Sheng, Xinan</creator><creator>Dai, Jie</creator><creator>Chi, Zhihong</creator><creator>Cui, Chuanliang</creator><creator>Kong, Yan</creator><creator>Fan, Yun</creator><creator>Xu, Yanjun</creator><creator>Wang, Xuan</creator><creator>Tang, Bixia</creator><creator>Lian, Bin</creator><creator>Yan, Xieqiao</creator><creator>Li, Siming</creator><creator>Zhou, Li</creator><creator>Wei, Xiaoting</creator><creator>Li, Caili</creator><creator>Guo, Jun</creator><creator>Zhang, Xiaoshi</creator><creator>Si, Lu</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20210824</creationdate><title>Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial</title><author>Mao, Lili ; Ding, Ya ; Bai, Xue ; Sheng, Xinan ; Dai, Jie ; Chi, Zhihong ; Cui, Chuanliang ; Kong, Yan ; Fan, Yun ; Xu, Yanjun ; Wang, Xuan ; Tang, Bixia ; Lian, Bin ; Yan, Xieqiao ; Li, Siming ; Zhou, Li ; Wei, Xiaoting ; Li, Caili ; Guo, Jun ; Zhang, Xiaoshi ; Si, Lu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c462t-7bba19d880485158ced74993777017813733a85b38a9f5ab26c6b83cabb5152b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>acral melanoma</topic><topic>BRAF</topic><topic>dabrafenib</topic><topic>melanoma</topic><topic>Oncology</topic><topic>trametinib</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mao, Lili</creatorcontrib><creatorcontrib>Ding, Ya</creatorcontrib><creatorcontrib>Bai, Xue</creatorcontrib><creatorcontrib>Sheng, Xinan</creatorcontrib><creatorcontrib>Dai, Jie</creatorcontrib><creatorcontrib>Chi, Zhihong</creatorcontrib><creatorcontrib>Cui, Chuanliang</creatorcontrib><creatorcontrib>Kong, Yan</creatorcontrib><creatorcontrib>Fan, Yun</creatorcontrib><creatorcontrib>Xu, Yanjun</creatorcontrib><creatorcontrib>Wang, Xuan</creatorcontrib><creatorcontrib>Tang, Bixia</creatorcontrib><creatorcontrib>Lian, Bin</creatorcontrib><creatorcontrib>Yan, Xieqiao</creatorcontrib><creatorcontrib>Li, Siming</creatorcontrib><creatorcontrib>Zhou, Li</creatorcontrib><creatorcontrib>Wei, Xiaoting</creatorcontrib><creatorcontrib>Li, Caili</creatorcontrib><creatorcontrib>Guo, Jun</creatorcontrib><creatorcontrib>Zhang, Xiaoshi</creatorcontrib><creatorcontrib>Si, Lu</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Open Access: DOAJ - Directory of Open Access Journals</collection><jtitle>Frontiers in oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mao, Lili</au><au>Ding, Ya</au><au>Bai, Xue</au><au>Sheng, Xinan</au><au>Dai, Jie</au><au>Chi, Zhihong</au><au>Cui, Chuanliang</au><au>Kong, Yan</au><au>Fan, Yun</au><au>Xu, Yanjun</au><au>Wang, Xuan</au><au>Tang, Bixia</au><au>Lian, Bin</au><au>Yan, Xieqiao</au><au>Li, Siming</au><au>Zhou, Li</au><au>Wei, Xiaoting</au><au>Li, Caili</au><au>Guo, Jun</au><au>Zhang, Xiaoshi</au><au>Si, Lu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial</atitle><jtitle>Frontiers in oncology</jtitle><addtitle>Front Oncol</addtitle><date>2021-08-24</date><risdate>2021</risdate><volume>11</volume><spage>720044</spage><epage>720044</epage><pages>720044-720044</pages><issn>2234-943X</issn><eissn>2234-943X</eissn><abstract>To examine the long-term survival outcome of dabrafenib in combination with trametinib in Chinese patients with unresectable or metastatic acral/cutaneous melanoma with BRAF-V600 mutation and to explore potential predictors of effectiveness. This was a long-term follow-up of Chinese patients with unresectable or metastatic BRAF V600-mutant acral/cutaneous melanoma administered dabrafenib (150 mg twice daily) plus trametinib (2 mg once daily) in an open-label, multicenter, single-arm, phase IIa study (NCT02083354). Efficacy endpoints included objective response rate (ORR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). The impacts of baseline characteristics on PFS and OS were analyzed. A total of sixty patients were included. The median age was 48 years, and 24 patients (40.0%) were male. Totally 12 individuals (20.0%) had acral melanoma, and 45 (75.0%) had failed previous systemic therapy. Up to July 2020, the median duration of follow-up was 37.0 (95% confidence interval [CI] 29.1-44.9) months. The updated ORR was 71.7% (95%CI 60.3%-83.1%). The 3-year OS rate was 28.8% (95%CI 19.1-43.6%) in the overall population, and 35.7% (95%CI 15.5-82.4%) in acral melanoma patients. The median DOR was 7.5 months (95%CI 4.5 to 10.5). Baseline normal lactic dehydrogenase (LDH), metastatic organ sites&lt;3 and complete response to combination therapy with dabrafenib plus trametinib were associated with improved PFS and OS. Dabrafenib combined with trametinib confer long-term survival in Chinese patients with BRAF V600-mutant, unresectable or metastatic acral/cutaneous melanoma. https://clinicaltrials.gov/ct2/show/NCT02083354, identifier NCT02083354.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>34504796</pmid><doi>10.3389/fonc.2021.720044</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2234-943X
ispartof Frontiers in oncology, 2021-08, Vol.11, p.720044-720044
issn 2234-943X
2234-943X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_3c16dfb2acaa443b86ee7bdc3445159e
source PubMed Central Free
subjects acral melanoma
BRAF
dabrafenib
melanoma
Oncology
trametinib
title Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T04%3A31%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Overall%20Survival%20of%20Patients%20With%20Unresectable%20or%20Metastatic%20BRAF%20V600-Mutant%20Acral/Cutaneous%20Melanoma%20Administered%20Dabrafenib%20Plus%20Trametinib:%20Long-Term%20Follow-Up%20of%20a%20Multicenter,%20Single-Arm%20Phase%20IIa%20Trial&rft.jtitle=Frontiers%20in%20oncology&rft.au=Mao,%20Lili&rft.date=2021-08-24&rft.volume=11&rft.spage=720044&rft.epage=720044&rft.pages=720044-720044&rft.issn=2234-943X&rft.eissn=2234-943X&rft_id=info:doi/10.3389/fonc.2021.720044&rft_dat=%3Cproquest_doaj_%3E2571924518%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c462t-7bba19d880485158ced74993777017813733a85b38a9f5ab26c6b83cabb5152b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2571924518&rft_id=info:pmid/34504796&rfr_iscdi=true